# Lipid Disorders and Atherosclerosis Prevention Starting in Youth

## Overview
Atherosclerosis is a lifelong process that begins with fatty streaks in childhood. The NHLBI Expert Panel recommends universal lipid screening in children at ages 9-11 and 17-21, a paradigm shift recognizing that pediatric lipid management can prevent adult cardiovascular disease. The Med-Peds physician is uniquely positioned to manage lipid disorders from initial detection in childhood through adult risk reduction.

## Pathophysiology: Atherosclerosis as a Pediatric Disease

### Evidence for Early Onset
**Bogalusa Heart Study**: autopsy studies of children and young adults showed fatty streaks in the aorta as early as age 3 and in coronary arteries by the teenage years. **PDAY Study (Pathobiological Determinants of Atherosclerosis in Youth)**: demonstrated that the extent of atherosclerosis in 15-34-year-olds correlated with antemortem risk factors (LDL, BMI, smoking, BP) **Muscatine Study**: childhood cholesterol levels predict adult lipid levels and subclinical atherosclerosis (carotid IMT) Key concept: the cumulative burden of LDL exposure over a lifetime determines cardiovascular risk (LDL-years or cholesterol-years hypothesis)

### Risk Factor Tracking
Childhood lipid levels track into adulthood with moderate-to-high correlation (r = 0.5-0.7) Risk factor clustering (dyslipidemia + obesity + hypertension + insulin resistance) begins in childhood and predicts metabolic syndrome in adulthood. Identifying children with elevated LDL provides a window for early intervention.

## Lipid Screening

### Pediatric Screening (NHLBI 2011 Integrated Guidelines)
**Universal screening**: fasting or non-fasting lipid panel at ages 9-11 and 17-21. **Selective screening**: ages 2-8 and 12-16 if positive family history of premature CVD or dyslipidemia, or if child has other risk factors (diabetes, obesity, HTN, CKD, smoking, Kawasaki with coronary aneurysms) Non-fasting non-HDL cholesterol is an acceptable initial screen (>145 mg/dL is abnormal) If non-fasting is abnormal, obtain fasting lipid panel.

### Adult Screening
USPSTF: screen all adults 40-75 for cardiovascular risk; use lipid panel as part of ASCVD risk calculation. ACC/AHA: fasting lipid panel every 4-6 years starting at age 20 in low-risk adults. More frequent monitoring if risk factors present.

### Pediatric Lipid Cutpoints (Ages 2-19, NHLBI)

| Parameter | Acceptable | Borderline | High/Low |
|-----------|-----------|------------|----------|
| Total cholesterol | <170 | 170-199 | >=200 |
| LDL-C | <110 | 110-129 | >=130 |
| Non-HDL-C | <120 | 120-144 | >=145 |
| HDL-C | >45 | 40-45 | <40 |
| Triglycerides (0-9y) | <75 | 75-99 | >=100 |
| Triglycerides (10-19y) | <90 | 90-129 | >=130 |

## Familial Hypercholesterolemia (FH)

### Genetics and Prevalence
Autosomal dominant; prevalence approximately 1:250 (heterozygous FH) Homozygous FH: 1:300,000-1:1,000,000; severe disease with cardiovascular events in childhood. Most common mutations: LDLR gene (most frequent), APOB, PCSK9 gain-of-function. Cascade screening of first-degree relatives when an index case is identified doubles detection rates.

### Clinical Features
**Heterozygous FH**: LDL typically 190-500 mg/dL; tendon xanthomas (Achilles, extensor tendons), corneal arcus, xanthelasma; premature CVD (men by 40s-50s, women by 50s-60s without treatment) **Homozygous FH**: LDL >500 mg/dL; planar xanthomas, tuberous xanthomas; aortic stenosis from supravalvular aortic deposits; MI and death in childhood/adolescence without treatment.

### Diagnosis
**Clinical criteria**: Dutch Lipid Clinic Network Score (adults), Simon Broome criteria. **Pediatric diagnosis**: LDL >=160 with family history of premature CVD or parental hypercholesterolemia; LDL >=190 without family history. **Genetic testing**: confirmatory but not required for diagnosis; identifies specific mutation for cascade screening.

### Management
Statins are first-line; recommended starting at age 8-10 in children with FH. LDL targets: <130 mg/dL (children); <100 mg/dL or >=50% reduction (adults with FH); <70 mg/dL (adults with ASCVD) Ezetimibe add-on if statin monotherapy insufficient. PCSK9 inhibitors (evolocumab, alirocumab): approved for FH in adults and adolescents >=12 (evolocumab); dramatic LDL reduction (50-60% additional lowering) Homozygous FH: may require LDL apheresis, lomitapide, evinacumab (ANGPTL3 inhibitor)

## Management of Dyslipidemia

### Lifestyle Modification (All Ages, First Step)
**Diet**: CHILD-1 diet (age 1-21, population-based) emphasizes reduced saturated fat (<10% calories), total fat 25-30% of calories, increased fiber; CHILD-2 diet for elevated LDL (<7% saturated fat) or elevated TG (reduced simple carbohydrates) **Exercise**: 60 min/day moderate-to-vigorous activity for children; 150 min/week for adults. **Weight management**: especially for hypertriglyceridemia and low HDL. Smoking avoidance/cessation. Adequate trial period: 6 months of lifestyle modification before pharmacotherapy in children (3-6 months in adults)

### Pharmacotherapy in Children

#### Statins
First-line for elevated LDL in children >=10 years (or >=8 years with FH and additional risk factors) FDA-approved pediatric statins: pravastatin (age 8+), rosuvastatin (age 8+), atorvastatin (age 10+), lovastatin (age 10+) Starting doses: lower than adult doses; titrate based on LDL response. Safety: well-tolerated in children in trials up to 10 years; no evidence of growth impairment, pubertal delay, or hormonal effects. Monitoring: baseline hepatic transaminases and CK; repeat at 4 weeks and with dose changes. Absolutely contraindicated in pregnancy -- counsel adolescent females about contraception.

#### Other Agents
**Ezetimibe**: add-on to statin if LDL goal not met; approved age 10+. **Bile acid sequestrants** (cholestyramine, colesevelam): alternative to statin in younger children; limited by palatability and GI side effects. **Fish oil (omega-3 fatty acids)**: for severe hypertriglyceridemia (>500 mg/dL to prevent pancreatitis) **PCSK9 inhibitors**: emerging role in adolescent FH.

### Pharmacotherapy in Adults

#### Statin Therapy (Cornerstone)
**High-intensity statin** (>=50% LDL reduction): atorvastatin 40-80 mg, rosuvastatin 20-40 mg. Indications: clinical ASCVD, LDL >=190, diabetes ages 40-75 with additional risk, 10-year ASCVD risk >=20%. **Moderate-intensity statin** (30-49% LDL reduction): atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40 mg. Indications: diabetes 40-75, 10-year ASCVD risk 7.5-19.9%, risk enhancers present. Statin intolerance: try alternative statin, lower dose, intermittent dosing (rosuvastatin 2-3x/week)

#### Non-Statin Therapies
**Ezetimibe**: 10 mg/day; 15-20% additional LDL reduction; IMPROVE-IT trial showed CV benefit. **PCSK9 inhibitors**: evolocumab (FOURIER), alirocumab (ODYSSEY); 50-60% LDL reduction; for FH or ASCVD not at goal on maximally tolerated statin + ezetimibe. **Bempedoic acid**: ACL inhibitor; CLEAR Outcomes trial showed benefit in statin-intolerant patients. **Inclisiran**: siRNA targeting PCSK9; twice-yearly injection; approved for ASCVD or FH. **Icosapent ethyl (Vascepa)**: REDUCE-IT trial; 25% RRR in CV events when added to statin in patients with TG 135-499 and ASCVD/diabetes.

## Risk Assessment

### Children and Adolescents
No validated 10-year ASCVD risk calculator for children. Risk stratification based on LDL level, family history, and comorbid conditions. NHLBI tiered approach: Tier I (highest risk: homozygous FH, diabetes, CKD, Kawasaki with coronary aneurysms, post-transplant), Tier II (moderate risk: heterozygous FH, moderate CKD, cancer survivors on cardiotoxic therapy), Tier III (at risk: obesity, HTN, metabolic syndrome)

### Adults
Pooled Cohort Equations (PCE): 10-year ASCVD risk calculator (age, sex, race, total cholesterol, HDL, SBP, DM, smoking, BP treatment) Risk enhancers: family history of premature ASCVD, metabolic syndrome, CKD, chronic inflammatory conditions, South Asian ancestry, elevated Lp(a), elevated hsCRP, ABI <0.9. Coronary artery calcium (CAC) scoring: useful for borderline-risk patients (5-7.5% or 7.5-20%); CAC = 0 may defer statin, CAC >=100 favors statin initiation.

<image>A timeline infographic showing the progression of atherosclerosis from childhood to adulthood. Starting at age 3 with fatty streaks in the aorta (Bogalusa Heart Study data), progressing through fibrous plaques in adolescence, calcified plaques in young adulthood, and vulnerable plaques with potential rupture and MI in middle age. Above the timeline, intervention windows are marked: lifestyle modification in childhood, lipid screening at ages 9-11, statin initiation at age 8-10 for FH, and adult ASCVD risk assessment at age 40. The cumulative LDL exposure (cholesterol-years) concept is illustrated as a shaded area under the LDL curve across the lifespan.</image>

<image>A clinical decision algorithm for managing elevated LDL in a child. Starting with a fasting lipid panel result showing LDL above 130 mg/dL, the flowchart branches to assess for secondary causes (hypothyroidism, nephrotic syndrome, medications), then evaluates family history and risk tier. For LDL 130-189 with family history, lifestyle modification for 6 months is recommended followed by statin if LDL remains above 160. For LDL 190 or above, FH is suspected, and statin therapy is recommended starting at age 8-10 with a target LDL below 130 or 50% reduction. Each decision node shows the NHLBI guideline reference.</image>

<image>A comparison table of lipid-lowering therapies available across the lifespan. Rows show drug classes (statins, ezetimibe, PCSK9 inhibitors, bile acid sequestrants, bempedoic acid, inclisiran, icosapent ethyl) with columns for: minimum age approved, expected LDL reduction percentage, landmark trial name, and key considerations. Statins and ezetimibe span from childhood to adulthood, while PCSK9 inhibitors bridge adolescence to adulthood, and newer agents (bempedoic acid, inclisiran) are adult-only. Color coding highlights pediatric-approved agents in blue and adult-only in gray.</image>

## Clinical Pearls
Atherosclerosis begins in childhood -- fatty streaks are present in the coronary arteries of teenagers, making lipid management a lifespan issue. Universal lipid screening is recommended at ages 9-11 and 17-21 (NHLBI guidelines) -- a non-fasting non-HDL cholesterol is an acceptable initial screen. Familial hypercholesterolemia affects 1:250 people and is vastly underdiagnosed -- any child with LDL >=190 should be evaluated for FH. Statins are safe and effective in children >=8-10 years -- no evidence of growth impairment in studies up to 10 years. Always counsel adolescent females on statins about the absolute contraindication in pregnancy. In adults, the decision to start a statin should integrate the 10-year ASCVD risk score, risk enhancers, and if borderline, coronary artery calcium scoring. PCSK9 inhibitors and inclisiran are game-changers for FH patients not at goal on maximally tolerated statin + ezetimibe. Cascade screening of first-degree relatives when FH is identified is one of the highest-yield genetic screening strategies in medicine.

## References
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents (NHLBI). Pediatrics. 2011;128(Suppl 5):S213-S256.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143.
- Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults (Bogalusa Heart Study). N Engl J Med. 1998;338(23):1650-1656.
- Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-2437.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER trial). N Engl J Med. 2017;376(18):1713-1722.